Familial Defective Apolipoprotein B-100 (FDB): A Comprehensive Disease Profile

Disease: Familial Defective Apolipoprotein B-100 (FDB) MONDO ID: MONDO:0007751 | OMIM: #144010 | Category: Mendelian (autosomal dominant / codominant)

Summary

Familial Defective Apolipoprotein B-100 (FDB) is a monogenic autosomal dominant (codominant) form of primary hypercholesterolemia caused by missense variants in the APOB gene that impair the ability of apolipoprotein B-100 (apoB-100) to bind the LDL receptor (LDLR). The archetypal and most common cause is the R3500Q variant (c.10580G>A; rs5742904; legacy p.Arg3500Gln, mature-protein numbering p.Arg3527Gln), which disrupts a critical intramolecular interaction between Arg3500 and Trp4369 that is required for apoB-100 to adopt the conformation necessary for normal LDLR engagement PMID: 11115503. Because defective LDL particles are cleared slowly from the plasma, LDL cholesterol (LDL-C) accumulates, leading to arterial LDL retention, macrophage foam-cell formation, tendon xanthomas, and premature atherosclerotic cardiovascular disease.

The R3500Q variant is a single European founder mutation that arose in an ancestor roughly 6,000–7,000 years ago (≈6,750 years; ~270 generations), and virtually all carriers worldwide are identical-by-descent PMID: 9339363. Clinically, FDB is a milder, frequently underdiagnosed cousin of LDLR-mediated familial hypercholesterolemia (FH): LDL-C elevation is on average ~1.2 mmol/L lower than in LDLR mutation carriers, coronary heart disease occurs less often and later, and standard clinical FH scoring criteria frequently fail to flag FDB carriers PMID: 15528480; PMID: 25126774; PMID: 18279815.

Because the LDL receptor is structurally intact in FDB, the disorder responds well to LDLR-upregulating pharmacotherapy — statins, ezetimibe, and PCSK9 inhibitors — and definitive diagnosis is molecular (single-gene codon-3500 assay or an NGS FH gene panel), enabling reverse-cascade screening of relatives PMID: 30910740; PMID: 29284604. Allelic heterogeneity exists at and near codon 3500 (R3500W, R3531C, R3480W, H3543Y), with R3500W being an important contributor to FH among East Asians PMID: 27919345; PMID: 15135245.

1. Disease Information

Overview. FDB is an inherited disorder of LDL catabolism in which a mutant apoB-100 — the sole apolipoprotein of LDL and the ligand recognized by the hepatic LDL receptor — binds the receptor with reduced affinity. The consequence is delayed clearance of LDL, elevated plasma LDL-C and apoB, and an increased lifetime risk of premature coronary artery disease. Clinically it is essentially indistinguishable from heterozygous LDLR-mediated FH without molecular testing; both present with elevated LDL-C, normal triglycerides and HDL-C, tendon xanthomas, and premature atherosclerosis PMID: 18325181.

Key identifiers.

Synonyms / alternative names. Familial ligand-defective apolipoprotein B-100; familial defective apoB-100; FDB; ligand-defective apoB; hypercholesterolemia due to ligand-defective apoB. FDB is one molecular subtype within the broader clinical umbrella of autosomal dominant hypercholesterolemia (ADH) / familial hypercholesterolemia (FH), alongside LDLR and PCSK9 causes PMID: 31883481.

Data source type. The knowledge in this report derives from aggregated disease-level resources — molecular genetics studies, FH registries, population cohorts (e.g., Copenhagen General Population Study), and functional/biochemical studies — rather than individual EHR-derived patient records.

2. Etiology

Primary cause — genetic. FDB is a monogenic disorder caused by heterozygous (or, rarely, homozygous/compound heterozygous) missense variants in APOB that localize to the LDLR-binding region of apoB-100 near codon 3500. The disease is not infectious or primarily environmental; environmental/lifestyle factors modify severity but do not cause the disorder.

Genetic risk factors. - Causal variant: APOB R3500Q (c.10580G>A; rs5742904) is the classic and most frequent cause. Additional ligand-defective variants clustering in the same functional region include R3500W, R3531C, R3480W, and H3543Y PMID: 15135245; PMID: 11115503. - Zygosity: heterozygotes are affected (codominant); homozygous APOB cases exist but are rare (e.g., 4 homozygous APOB patients among 49 molecularly defined homozygous ADH cases in the Netherlands) PMID: 24585268.

Environmental / modifying risk factors. Background diet (saturated fat, cholesterol intake), obesity, smoking, and coexisting metabolic syndrome raise absolute LDL-C and cardiovascular risk on top of the genetic defect. Phenotypic expression depends jointly on the mutation and the genetic/dietary background of the population studied; ascertainment in lipid clinics overestimates the true population effect size PMID: 15528480.

Protective factors. Because the underlying lesion is impaired receptor-mediated LDL clearance, any factor that upregulates LDLR expression or lowers LDL production is protective — this is the pharmacological basis of statins, ezetimibe, and PCSK9 inhibition. Rare APOB missense variants can also lower LDL (e.g., an apoB S2429T variant proposed to have an LDL-lowering effect within an FH family), illustrating that APOB variation can push LDL in either direction PMID: 27578127; PMID: 7585299.

Gene–environment interactions. The measured LDL-C increment attributable to a given APOB or LDLR variant differs by background population and by ascertainment context — general-population carriers and clinically ascertained FH carriers differed by ~1.6 mmol/L (P=0.03) — confirming that the phenotype is a product of genotype × background/lifestyle rather than genotype alone PMID: 15528480.

3. Phenotypes

FDB phenotypes are those of heterozygous FH but generally milder.

Severity and progression. LDL-C elevation is stable/lifelong; atherosclerosis is slowly progressive. Notably, FH/high-LDL-C (including APOB R3500Q) increases myocardial-infarction risk but not ischemic stroke risk in the general population PMID: 29593013.

Quality of life. No FDB-specific EQ-5D/SF-36 data were identified. QoL impact derives chiefly from cardiovascular events and lifelong pharmacotherapy; because FDB is generally milder and later-onset than LDLR-FH, the average burden is correspondingly lower.

4. Genetic / Molecular Information

Causal gene. APOB (apolipoprotein B; HGNC:603; OMIM *107730), chromosome 2p24–23. ApoB-100 (4,536 residues in the mature protein) is the structural scaffold of VLDL/IDL/LDL and the LDLR ligand.

Pathogenic variants.

Variant classification (ACMG/AMP). R3500Q is well established as pathogenic (functional evidence of defective LDLR binding, cosegregation, founder haplotype). Several additional exon 26/29 variants (e.g., S3476L, S3488G, Y3533C, T3540M, I4350T, G4368D) have been reported as FDB-associated in Dutch cohorts and warrant case-by-case interpretation PMID: 18325181.

Allele frequency. R3500Q carrier frequency is on the order of ~0.1% (≈1 in 500–1,000) in Northern/Central European populations, lower in Southern Europe (e.g., rare in general Spain but locally enriched in Galicia due to Celtic ancestry) PMID: 12208478.

Somatic vs germline. Germline; there is no somatic component.

Functional consequence. A conformational loss-of-ligand-function: the variant does not abolish the protein but changes the local conformation around the receptor-binding site, reducing LDLR affinity to ~32% of normal PMID: 10657378. This behaves as a dominant/codominant trait because each affected allele produces defective LDL particles.

Modifier genes. Polygenic LDL-raising SNP burden and coexisting variants in other lipid genes (LDLR, PCSK9, APOE, ANGPTL3, APOC3) modulate expressivity; rare APOB variants (e.g., S2429T) may lower LDL and partially offset severity PMID: 27578127; PMID: 31883481.

Epigenetic / chromosomal. No recurrent epigenetic mechanism or chromosomal abnormality is implicated in FDB; it is a point-mutation disorder.

5. Environmental Information

• Environmental factors: No specific toxin, radiation, or occupational exposure causes FDB.
• Lifestyle factors: Dietary saturated fat/cholesterol, obesity, physical inactivity, and smoking increase absolute LDL-C and atherosclerotic risk on top of the genetic defect and are the primary modifiable levers.
• Infectious agents: None. FDB is a purely genetic, non-communicable disorder.

6. Mechanism / Pathophysiology

Ordered causal chain

1. A germline missense variant in APOB (most commonly R3500Q) is inherited → leads to an amino-acid substitution in apoB-100 at/near the LDLR-binding region.
2. The substitution disrupts the intramolecular Arg3500–Trp4369 interaction (and requires the apoB-100 C-terminus) → results in an altered local conformation of apoB-100 around the receptor-binding site (demonstrated by higher affinity for the conformation-sensitive MB47 antibody) PMID: 11115503.
3. The altered conformation → reduces binding of LDL particles to the hepatic LDL receptor (to ~32% of normal affinity) PMID: 10657378.
4. Reduced receptor binding → decreases receptor-mediated hepatic uptake/catabolism of LDL → prolongs LDL residence time in plasma.
5. Delayed clearance → raises plasma LDL-C and apoB concentrations (the biochemical phenotype).
6. Elevated (and modified/oxidized) LDL → accumulates and is retained in the arterial intima.
7. Retained LDL → is internalized by macrophages → drives foam-cell formation and an immune-inflammatory response PMID: 33959626.
8. Chronic foam-cell/inflammatory burden → produces atherosclerotic plaques → manifests clinically as tendon xanthomas and premature coronary artery disease PMID: 18325181.

APOB R3500Q mutation
   │ (disrupts Arg3500–Trp4369)
   ▼
apoB-100 conformational change near LDLR-binding site   [upstream, causal]
   ▼
↓ LDL–LDLR binding affinity (~32% of normal)
   ▼
↓ hepatic LDL clearance → ↑ LDL residence time
   ▼
↑ plasma LDL-C / apoB
   ▼
arterial intimal LDL retention ──► macrophage uptake ──► foam cells + inflammation
   ▼
atherosclerosis ──► tendon xanthomas + premature CAD   [downstream, clinical]

Upstream vs downstream. The conformational defect and reduced receptor binding are the upstream initiating lesions; hypercholesterolemia is the intermediate biochemical readout; foam-cell formation and atherosclerosis are downstream consequences shared with all LDL-driven hypercholesterolemias.

Molecular pathways / cellular processes. Receptor-mediated endocytosis of LDL (KEGG hsa04979, "Cholesterol metabolism"); reverse cholesterol transport (ABCA1-mediated efflux); macrophage lipid handling and NF-κB-driven vascular inflammation are engaged downstream PMID: 33568202; PMID: 36838686.

Protein dysfunction. Conformational loss-of-ligand-function of apoB-100 (not misfolding/aggregation, not loss of expression). UniProt P04114 (APOB_HUMAN).

Metabolic changes. Isolated elevation of LDL-C and apoB with characteristically normal triglycerides and HDL-C — distinguishing FDB from combined hyperlipidemias.

Suggested ontology terms. GO:0006629 (lipid metabolic process); GO:0034383 (low-density lipoprotein particle clearance); GO:0006898 (receptor-mediated endocytosis); GO:0034364 (low-density lipoprotein particle); CHEBI:39025 (low-density lipoprotein). Cell types: CL:0000182 (hepatocyte), CL:0000235 (macrophage/foam cell), CL:0000891 (aortic/vascular smooth muscle context).

7. Anatomical Structures Affected

• Primary organ: Liver (hepatocytes) — the principal site of LDL-receptor-mediated clearance whose function is bypassed by the defective ligand. UBERON:0002107 (liver); CL:0000182 (hepatocyte).
• Secondary/target organs: Arterial wall, especially coronary arteries (and femoral/peripheral arteries). UBERON:0001981 (blood vessel); UBERON:0001621 (coronary artery). Femoral intima-media thickness is increased in FH patients including APOB defects, in relation to mutational class PMID: 18096825.
• Body systems: Cardiovascular (atherosclerosis, CAD) and integumentary/musculoskeletal (tendon xanthomas). Blood/plasma lipoprotein compartment is the biochemical stage.
• Tissue/cell level: Vascular intima (connective tissue), arterial macrophages/foam cells (CL:0000235), and hepatocytes.
• Subcellular: Plasma-membrane LDL receptor and clathrin-coated pits (GO:0005905); endosomes/lysosomes for LDL degradation (GO:0005764). The extracellular lipoprotein particle (GO:0034364) is the affected entity.
• Lateralization: Systemic/bilateral (xanthomas often symmetric); vascular disease is diffuse rather than lateralized.

8. Temporal Development

• Onset: The biochemical trait (elevated LDL-C/apoB) is congenital and lifelong. Clinical complications are adult-onset, typically later than in LDLR-FH.
• Onset pattern: Chronic/insidious.
• Progression: Slowly progressive atherosclerosis. FDB CHD occurs at a mean age of ~52 years versus ~41 years in LDLR-FH, and far less frequently (5.6% vs 41.8%) PMID: 25126774.
• Course: Stable biochemical elevation with progressive vascular risk; chronic lifelong disease.
• Critical window: Cumulative LDL exposure drives risk, so the critical period for intervention is early and sustained LDL lowering from young adulthood (or childhood in higher-risk cases), before substantial plaque burden accrues.

9. Inheritance and Population

Inheritance. Autosomal dominant / codominant; heterozygotes are affected. Homozygous/compound-heterozygous APOB cases are rare and more severe PMID: 24585268.

Penetrance / expressivity. Biochemical penetrance is high but expressivity is variable — some carriers have LDL-C within the normal range, and clinical FH scores (Dutch Lipid Clinic Network, Simon Broome) have low sensitivity for APOB variants (DLCN sensitivity 13.8%; SBDC 22.5%) PMID: 30270060; PMID: 18279815.

Founder effect. R3500Q is a single European founder mutation ~6,000–7,000 years old (≈270 generations); all probands are identical-by-descent, carried on the rare APOB haplotype 194 (XbaI−/MspI+/EcoRI−) PMID: 9339363; PMID: 12208478.

Epidemiology. Estimated carrier frequency ~0.1% (≈1 in 500–1,000) in Northern/Central Europe; combined LDLR+APOB FH prevalence ~1 in 125–135 in Switzerland, with FDB a minority subtype PMID: 30270060. FDB is a minor cause of clinically diagnosed FH in Southern Europe (e.g., 1.4% of Spanish clinical-FH probands; population prevalence ~2.8×10⁻⁵), but locally enriched in Galicia PMID: 12208478; PMID: 16596945.

Population distribution of variants. R3500Q predominates in European-descent populations; R3500W is the major ligand-defective APOB variant in East Asians (identified in 8 Taiwanese FH probands; heterozygote prevalence 2.4% vs 0.3% for R3500Q in Chinese hyperlipidemics) PMID: 20538126; PMID: 10998466.

Sex ratio / consanguinity. No strong sex bias (autosomal dominant); consanguinity is not required for the dominant heterozygous phenotype but underlies rare homozygous cases.

10. Diagnostics

Laboratory. Elevated LDL-C and apoB with normal triglycerides and HDL-C (LOINC: 13457-7 LDL-C; 1884-6 apoB) PMID: 18325181. A functional flow-cytometric LDL-ligand assay can detect heterozygous FDB by demonstrating reduced LDL binding PMID: 10657378.

Genetic testing (definitive). FDB cannot be distinguished clinically from LDLR-FH and requires molecular confirmation PMID: 18325181. Approaches: - Targeted single-variant/codon-3500 assays (PCR-RFLP, high-resolution melting) for R3500Q/H3543Y PMID: 18325181. - NGS FH gene panels covering LDLR, APOB, PCSK9 (± LDLRAP1, ABCG5/8) PMID: 41412630; PMID: 41760042. - WES/WGS are useful when panels are negative.

Clinical criteria & differential diagnosis. DLCN and Simon Broome criteria are standard for FH but under-detect FDB PMID: 30270060. Differential diagnosis includes LDLR-mediated FH, PCSK9 gain-of-function FH, polygenic hypercholesterolemia, familial combined hyperlipidemia PMID: 34906840, and rare recessive/other catabolic defects (a clinical HoFH phenotype has been reported with intact apoB/LDLR, implying additional catabolic genes) PMID: 9626156.

Screening. Cascade (reverse-cascade) screening of first-degree relatives after an index molecular diagnosis is the key strategy; universal newborn/pediatric screening for FH is supported by healthcare professionals but not yet routine PMID: 41251905; PMID: 41608359.

11. Outcome / Prognosis

• Survival/mortality: No FDB-specific survival tables identified. Prognosis is driven by cardiovascular event risk, which is lower and later than in LDLR-FH.
• Morbidity: Premature CAD is the dominant morbidity; CHD prevalence ~5.6% in FDB vs 41.8% in LDLR-FH PMID: 25126774. FH/high LDL-C raises myocardial infarction risk but not ischemic stroke risk PMID: 29593013.
• Prognostic factors: Mutational class (null LDLR alleles > receptor-defective > APOB defects for atherosclerosis severity and LDL-C), absolute/cumulative LDL-C, age, sex, smoking, and blood pressure PMID: 18096825; PMID: 28475941.
• Recovery potential: With early sustained LDL lowering, cardiovascular risk is substantially reducible; the intact LDL receptor predicts good pharmacologic response.

12. Treatment

FDB is managed as heterozygous FH, and — critically — because the LDL receptor itself is intact, LDLR-upregulating therapies are highly effective.

Rationale. "There is today a large availability of drugs (i.e., statins, ezetimibe and PCSK9 inhibitors) allowing theoretically the normalization of plasma LDL cholesterol levels in this population" PMID: 30910740. Because FDB LDL clearance depends on functional LDLR, upregulating the receptor compensates for the ligand defect — mechanistically supported by the observation that "Mevastatin increased, whereas rPCSK9 reduced LDLR expression. The PCSK9-neutralizing antibody restored LDLR expression" PMID: 29284604.

Experimental / advanced. Gene- and cell-based therapies (LDLR gene delivery, CRISPR/Cas9 editing) are in development primarily for homozygous FH; RNA therapies and MTP/ANGPTL3-directed agents extend options for severe/refractory disease PMID: 36572377; PMID: 30910740.

Personalized medicine. Molecular subtyping (APOB vs LDLR-null vs LDLR-defective) informs prognosis and intensity of therapy; genotype-guided cascade screening extends benefit to relatives PMID: 41412630.

13. Prevention

• Primary prevention: Lifelong healthy diet, avoidance of smoking, weight and blood-pressure control to minimize cumulative atherosclerotic risk.
• Secondary prevention (early detection): Reverse-cascade genetic and lipid screening of relatives after an index diagnosis; consideration of pediatric/newborn FH screening PMID: 41251905; PMID: 41608359.
• Tertiary prevention: Aggressive LDL lowering (statin ± ezetimibe ± PCSK9 inhibitor) to prevent CAD progression and events.
• Genetic counseling: 50% transmission risk per offspring (autosomal dominant); counseling supports family planning and cascade testing PMID: 41412630.

14. Other Species / Natural Disease

• Taxonomy/orthologs: APOB is conserved across mammals (human APOB, NCBI Gene 338; mouse Apob, NCBI Gene 238). No specific naturally occurring animal disease attributable to an APOB R3500Q-equivalent variant was identified in this investigation.
• Comparative biology: The apoB-100/LDLR clearance axis is evolutionarily conserved, and the mechanism has been functionally validated in transgenic mice expressing human R3500Q and W4369Y apoB, which reproduce the defective LDLR binding PMID: 11115503.
• Transmission/zoonosis: Not applicable — non-communicable genetic disorder.

15. Model Organisms

• Transgenic mice: Mice expressing human apoB-100 carrying R3500Q (and the complementary W4369Y) were pivotal in defining the mechanism — LDL from both showed identically defective LDLR binding and increased MB47 antibody affinity, demonstrating the Arg3500–Trp4369 conformational interaction PMID: 11115503.
• In vitro / cellular models: Cultured cells (e.g., fibroblasts, HepG2-type systems) are used to quantify LDLR expression and LDL binding under statin/PCSK9 modulation, and to test LDLR-upregulating therapeutics PMID: 29284604. Macrophage foam-cell models (e.g., RAW264.7, ApoE-deficient mouse aortas) recapitulate the downstream atherosclerotic steps PMID: 33568202; PMID: 36838686.
• Phenotype recapitulation: Transgenic mice faithfully reproduce the ligand-binding defect (the core lesion). Limitation: murine lipoprotein metabolism differs from human, so absolute LDL-C phenotype and atherosclerosis burden require sensitized backgrounds (e.g., ApoE-deficient) and do not fully mirror human clinical disease.
• Resources: MGI (mouse Apob), Cellosaurus/ATCC (cell lines).

Mechanistic Model / Interpretation

FDB is best understood as a ligand-side mirror image of LDLR-mediated FH: in classic FH the receptor is broken, whereas in FDB the ligand (apoB-100) is broken. Both converge on the same downstream pathology — impaired LDL clearance → hypercholesterolemia → arterial LDL retention → foam cells → atherosclerosis — but they differ quantitatively. The single conformational contact point (Arg3500–Trp4369) is the linchpin: substituting Arg3500 (a specific arginine, not merely any positive charge) collapses the receptor-competent conformation, cutting binding to ~32% of normal. Because only the ligand on the mutant allele is defective and the receptor pool is fully functional, (a) heterozygotes retain substantial clearance capacity (hence a milder phenotype and frequent underdiagnosis), and (b) upregulating the intact receptor pharmacologically (statins, PCSK9 inhibitors) efficiently rescues clearance. This mechanistic logic explains, in one coherent chain, the biochemistry, the milder-than-LDLR-FH clinical course, and the excellent drug response.

Evidence Base

Limitations and Knowledge Gaps

1. No primary omics data were analyzed in this investigation; conclusions rest on literature synthesis of genetics, biochemistry, and clinical registries.
2. FDB-specific epidemiology is imprecise — carrier-frequency estimates vary widely by population and ascertainment; robust general-population prevalence figures for R3500Q specifically remain limited.
3. Nomenclature ambiguity — legacy (R3500Q) vs mature-protein (R3527Q) vs full-length numbering can cause confusion; reports should standardize to HGVS.
4. Variant classification for non-R3500Q APOB variants (e.g., the Dutch exon-26/29 variants) is incomplete; several remain of uncertain functional impact.
5. No dedicated QoL, survival, or mortality datasets specific to FDB were located.
6. Model-organism fidelity — transgenic mice capture the ligand defect but not the full human atherosclerotic phenotype without sensitizing backgrounds.
7. Non-European populations are under-studied; R3500W in East Asians is documented but broad allelic surveys are sparse.

Proposed Follow-up Experiments / Actions

1. Query gnomAD directly for population-stratified allele frequencies of rs5742904 (R3500Q) and R3500W to quantify carrier frequencies with confidence intervals.
2. Pull ClinVar/ClinGen classifications for all APOB codon-3480 to 3543 variants to build a definitive pathogenicity table with ACMG criteria.
3. Systematic outcomes meta-analysis comparing cardiovascular event rates and treated LDL-C in molecularly confirmed FDB vs LDLR-FH cohorts (e.g., SAFEHEART, DIAMOND-FH data).
4. Structural analysis (AlphaFold/PDB) of the apoB-100 receptor-binding region to visualize the Arg3500–Trp4369 contact and model each ligand-defective variant's disruption.
5. Real-world PCSK9-inhibitor response study in genotyped FDB patients to confirm the predicted superior response given intact LDLR.
6. Cascade-screening yield analysis to quantify how many relatives per index FDB case are newly diagnosed and treated, informing cost-effectiveness of molecular-first screening.

Report compiled from 40 reviewed papers and 6 confirmed findings across 5 investigation iterations. Evidence types span human clinical/registry studies, transgenic mouse and in-vitro functional work, and population genetics. All mechanistic and clinical claims are cited to primary literature (PMIDs above).